Please assess the completion status of the following clinical trial:

Trial Title: Phase 1 Study of Vorinostat and Bortezomib in Multiple Myeloma (MK-0683-015 EXT 1 (AM1))

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Adults with refractory or relapsed multiple myeloma~* Eastern Cooperative Oncology Group (ECOG) performance status of 0-2 (a measurement to determine participant's ability to perform daily activities)~* Adequate bone marrow reserve~* Adequate hepatic and renal function~* Ability to swallow capsules~* 3 weeks or more since prior chemotherapy and have recovered from prior toxicities~Exclusion Criteria:~* Participants who plan to have a bone marrow transplant within 4 weeks of start of treatment~* Participants with prior treatment with other investigational agents with a similar anti-tumor mechanism~* Participants with other active/uncontrolled clinically significant illness~* Pregnant or nursing female participants~* Participants who received bortezomib within 3 months of start of this trial

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- vorinostat 200 mg + bortezomib 0.7 mg/m^2 (Type: EXPERIMENTAL): Vorinostat capsules given twice daily (b.i.d.); bortezomib injection given on Days 4, 8, 11, and 15 of each cycle.
- vorinostat 200 mg + bortezomib 0.9 mg/m^2 (Type: EXPERIMENTAL): Vorinostat capsules given b.i.d.; bortezomib injection given on Days 4, 8, 11, and 15 of each cycle.
- vorinostat 300 mg + bortezomib 1.3 mg/m^2 (Type: EXPERIMENTAL): Vorinostat given once daily (q.d.); bortezomib given on Days 1, 4, 8, and 11 of each cycle.
- vorinostat 400 mg + bortezomib 0.9 mg/m^2 (Type: EXPERIMENTAL): Vorinostat given q.d.; bortezomib given on Days 1, 4, 8, and 11 of each cycle.
- vorinostat 400 mg + bortezomib 1.1 mg/m^2 (Type: EXPERIMENTAL): Vorinostat given q.d.; bortezomib given on Days 1, 4, 8, and 11 of each cycle.
- vorinostat 400 mg + bortezomib 1.3 mg/m^2 (Type: EXPERIMENTAL): Vorinostat given q.d.; bortezomib given on Days 1, 4, 8, and 11 of each cycle.

Based on this trial design, predict the completion outcome and termination type (if applicable).